XORTX Therapeutics Inc.
XRTX
$2.28
-$0.03-1.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -109.12% | -36.92% | 9.08% | 9.50% | -2.72% |
| Total Depreciation and Amortization | -29.07% | -11.34% | -1.02% | 6.52% | 6.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 365.57% | 93.07% | -34.35% | 61.31% | 28.87% |
| Change in Net Operating Assets | -660.72% | 647.43% | -193.75% | -14.89% | -75.35% |
| Cash from Operations | -551.70% | 28.57% | -11.48% | 20.66% | -23.27% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,665.82% | 97.01% | -4,705.45% | 74.77% | -541.18% |
| Cash from Investing | -1,665.82% | 97.01% | -4,705.45% | 74.77% | -541.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 31.98% | -1.83% | -1.87% | 8.15% | -0.87% |
| Issuance of Common Stock | -- | -- | 6.06% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -909.39% | 81.70% | -81.31% | -1,123.76% | 11.40% |
| Cash from Financing | 4,089.73% | -116.47% | -17.95% | 1,876.27% | -164.20% |
| Foreign Exchange rate Adjustments | -700.00% | -119.05% | 179.25% | -119.63% | 2,354.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 221.10% | -86.46% | -352.61% | 115.68% | -43.81% |